HBMH.F logo

HBM Holdings LimitedOTCPK:HBMH.F Stock Report

Market Cap US$1.4b
Share Price
n/a
1Yn/a
7D0%
Portfolio Value
​
View

HBM Holdings Limited

OTCPK:HBMH.F Stock Report

Market Cap: US$1.4b

HBM Holdings (HBMH.F) Stock Overview

A biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. More details

HBMH.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends0/6

Rewards

Price-To-Earnings ratio (15x) is below the US market (18.4x)

Earnings grew by 3187.7% over the past year

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

Earnings are forecast to decline by an average of 4.9% per year for the next 3 years


HBMH.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,300 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
440,300 investors already sharing narratives
View all narratives

HBM Holdings Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for HBM Holdings
Historical stock prices
Current Share PriceHK$1.56
52 Week HighHK$2.54
52 Week LowHK$1.56
Beta1.4
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO227.11%

Recent News & Updates

Recent updates

Shareholder Returns

HBMH.FUS BiotechsUS Market
7D0%-5.3%-1.0%
1Yn/a37.0%14.1%

Return vs Industry: Insufficient data to determine how HBMH.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how HBMH.F performed against the US Market.

Price Volatility

Is HBMH.F's price volatile compared to industry and market?
HBMH.F volatility
HBMH.F Average Weekly Movementn/a
Biotechs Industry Average Movement9.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: HBMH.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine HBMH.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016210Jingsong Wangwww.harbourbiomed.com

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm.

HBM Holdings Limited Fundamentals Summary

How do HBM Holdings's earnings and revenue compare to its market cap?
HBMH.F fundamental statistics
Market capUS$1.37b
Earnings (TTM)US$91.33m
Revenue (TTM)US$157.98m
15.0x
P/E Ratio
8.7x
P/S Ratio

Is HBMH.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HBMH.F income statement (TTM)
RevenueUS$157.98m
Cost of RevenueUS$8.73m
Gross ProfitUS$149.24m
Other ExpensesUS$57.91m
EarningsUS$91.33m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.11
Gross Margin94.47%
Net Profit Margin57.81%
Debt/Equity Ratio20.0%

How did HBMH.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/18 03:03
End of Day Share Price 2026/02/18 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HBM Holdings Limited is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Jin ZhangChina International Capital Corporation Limited
Tony RenCLSA